Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632103 | 0.88 | ALDH1A1 (0.53) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL29664618 | 0.88 | ALDH1A1 (0.53) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL7035557 | 0.87 | ALDH1A1 (0.52) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL11044502 | 0.87 | PPARD (0.55) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL3660001 | 0.85 | PPARD (0.57) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL3658911 | 0.85 | PPARD (0.54) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL3302212 | 0.84 | PPARD (0.52) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL3298167 | 0.84 | PPARD (0.52) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL538994 | 0.83 | KMT2A (0.55) | CA12ALDH1A1CA1CA2TSHR | |
| SCHEMBL538636 | 0.83 | PPARD (0.58) | TSHRPPARDMAOBPLA2G2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589125-B2 | 2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate; psoriasis and other immune diseases | PALAU PHARMA, S.A. (ES) | 2009-09-15 | — | — | US | claimed |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | J. URIACH Y COMPANIA S.A. (ES) | 2005-12-01 | — | — | US | claimed |
| EP-1546084-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach y Compania S.A. (ES) | 2005-06-29 | — | — | EP | claimed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | claimed |
| US-7589125-B2 | 2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate; psoriasis and other immune diseases | PALAU PHARMA, S.A. (ES) | 2009-09-15 | — | — | US | disclosed |
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | J. URIACH Y COMPANIA S.A. (ES) | 2005-12-01 | — | — | US | disclosed |
| EP-1546084-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach y Compania S.A. (ES) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | CA12 2570/4885ALDH1A1 458/4885CA1 2130/4885 |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | CYP24A1, NFKBIA, PAH | CA12 1530/4885ALDH1A1 101/4885CA1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.